Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
Maria Luisa Brandi, Gema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, Karine Briot, Carmen de Lucas Collantes, Francesco Emma, Sandro Giannini, Dieter Haffner, Richard Keen, Elena Levtchenko, Outi Mӓkitie, Ola Nilsson, Dirk Schnabel, Liana Tripto-Shkolnik, M Carola Zillikens, Jonathan Liu, Alina Tudor, M Zulf Mughal, Maria Luisa Brandi, Gema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, Karine Briot, Carmen de Lucas Collantes, Francesco Emma, Sandro Giannini, Dieter Haffner, Richard Keen, Elena Levtchenko, Outi Mӓkitie, Ola Nilsson, Dirk Schnabel, Liana Tripto-Shkolnik, M Carola Zillikens, Jonathan Liu, Alina Tudor, M Zulf Mughal
Abstract
Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH)2D) synthesis. Disease characteristics include rickets, osteomalacia, odontomalacia, and short stature. Historically, treatment has been oral phosphate and 1,25(OH)2D supplements. However, these treatments do not correct the primary pathogenic mechanism or treat all symptoms and can be associated with adverse effects. Burosumab is a recombinant human immunoglobulin G1 monoclonal antibody against FGF23, approved for treating XLH in several geographical regions, including Europe and Israel. Burosumab restores normal serum phosphate levels, minimising the clinical consequences of XLH. Safety data on long-term treatment with burosumab are lacking owing to the rarity of XLH. This post-authorisation safety study (PASS) aims to evaluate the safety outcomes in patients aged >1 year.
Methods: The PASS is a 10-year retrospective and prospective cohort study utilising data from the International XLH Registry (NCT03193476), which includes standard diagnostic and monitoring practice data at participating centres. The PASS aims to evaluate frequency and severity of safety outcomes, frequency and outcomes of pregnancies in female patients, and safety outcomes in patients with mild to moderate kidney disease at baseline, in children, adolescents and adults treated with burosumab for XLH. It is expected that there will be at least 400 patients who will be administered burosumab.
Results: Data collection started on 24 April 2019. The expected date of the final study report is 31 December 2028, with two interim reports.
Conclusion: This PASS will provide data on the long-term safety of burosumab treatment for XLH patients and describe safety outcomes for patients receiving burosumab contrasted with those patients receiving other XLH treatments, to help inform the future management of XLH patients. The PASS will be the largest real-world safety study of burosumab.
Registry identification: The International XLH Registry is registered with clinicaltrials.gov as NCT03193476 (https://ichgcp.net/clinical-trials-registry/NCT03193476), and the PASS is registered with the European Union electronic Register of Post-Authorisation Studies as EUPAS32190 (http://www.encepp.eu/encepp/viewResource.htm?id=32191).
Keywords: X-linked hypophosphataemia (XLH); burosumab; patient registry; phosphate; post-authorisation safety study (PASS); rare bone disease; real-world evidence.
Conflict of interest statement
Competing interests: AB has received research grants and received honoraria as a consultant and speaker, paid to her institution, from Kyowa Kirin and Ultragenyx. CLC has received honoraria as a consultant for Kyowa Kirin. MCZ reports that her institution has received a research grant from Kyowa Kirin. DH has received a research grant or honoraria as a consultant and speaker from Amgen, Chiesi and Kyowa Kirin. DS has received honoraria as a consultant from BioMarin, Kyowa Kirin, Novo Nordisk and Sandoz. EL has received honoraria as a consultant from Advicenne, Chiesi, Kyowa Kirin, Novartis and Recordati. FE declares competing interests with Avrobio, Chiesi, Kyowa Kirin, Otsuka and Recordati Rare Diseases. GA has received personal fees and non-financial support from Advicenne, Alexion, Kyowa Kirin, Recordati Rare Diseases and received personal fees from Alnylam and Dicerna, and received personal fees and other from Chiesi. KB has received honoraria as a consultant from Amgen, Kyowa Kirin, Theramex and UCB. LTS has received honoraria as a consultant from Amgen and Kyowa Kirin. MB has received research grants or honoraria as a consultant or speaker from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Calilytix, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex and UCB. ON has received honoraria as a consultant from BioMarin and Kyowa Kirin. OM has received honoraria as a consultant from BridgeBio, Kyowa Kirin and Ultragenyx. RK has received honoraria as a consultant or for advisory boards from Kyowa Kirin. SBN and ZM have received honoraria as a consultant or speaker from Inozyme Pharma and Kyowa Kirin. JL and AT are employees of Kyowa Kirin International plc. SG declares no conflict of interests.
© The Author(s), 2022.
Figures
References
- Endo I, Fukumoto S, Ozono K, et al.. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015; 62: 811–816.
- Rafaelsen S, Johansson S, Raeder H, et al.. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 2016; 174: 125–136.
- Hawley S, Shaw NJ, Delmestri A, et al.. Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis. J Clin Endocrinol Metab 2020; 105: e871–e878.
- Beck-Nielsen SS, Brock-Jacobsen B, Gram J, et al.. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 2009; 160: 491–497.
- Haffner D, Emma F, Eastwood DM, et al.. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019; 15: 435–455.
- Beck-Nielsen SS, Mughal Z, Haffner D, et al.. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 2019; 14: 58.
- Whyte MP, Schranck FW, Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 1996; 81(11): 4075–4080.
- Chesher D, Oddy M, Darbar U, et al.. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 2018; 41: 865–876.
- Padidela R, Nilsson O, Makitie O, et al.. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare Dis 2020; 15: 172.
- Carpenter TO, Imel EA, Holm IA, et al.. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26: 1381–1388.
- Skrinar A, Dvorak-Ewell M, Evins A, et al.. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 2019; 3: 1321–1334.
- Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Eur J Pediatr 1998; 157(11): 894–900.
- Makitie O, Doria A, Kooh SW, et al.. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003; 88: 3591–3597.
- Quinlan C, Guegan K, Offiah A, et al.. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012; 27: 581–588.
- European Medicines Agency. Crystvita summary of product characteristics, (2021, accessed 4 August 2021).
- European Medicines Agency. New medicine for rare bone disease, (2017, accessed 5 August 2021).
- Carpenter TO, Imel EA, Ruppe MD, et al.. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 2014; 124: 1587–1597.
- Carpenter TO, Whyte MP, Imel EA, et al.. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 2018; 378: 1987–1998.
- Portale AA, Carpenter TO, Brandi ML, et al.. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 2019; 105: 271–284.
- Bassanese G, Wlodkowski T, Servais A, et al.. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet J Rare Dis 2021; 16: 251.
- Viviani L, Zolin A, Mehta A, et al.. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis 2014; 9: 81.
- Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A 2018; 176(4): 773–783.
- Haase R, Wunderlich M, Dillenseger A, et al.. Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. Expert Opin Drug Saf 2018; 17: 369–378.
- Cottin V, Koschel D, Gunther A, et al.. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res 2018; 4: 84.
Source: PubMed